Instrument Inactif

Communiqués Torii Pharmaceutical Co., Ltd.

Actions

4551

JP3635800000

Produits pharmaceutiques

Communiqués

27/08/25	Torii Pharmaceutical : Announcement of Delisting of Company Stock（PDF）	PU
19/06/25	Torii Pharmaceutical : Announcement of Results of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Changes in an Other Associated Company and a Major Shareholder（PDF）	PU
05/06/25	Torii Pharmaceutical : (Amendment) Partial amendments to the “Announcement of Expression of Opinion in Support of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Recommendation to Tender Shares in the Tender Offer”（PDF）	PU
05/06/25	Torii Pharmaceutical : Our Relationship with Patent Infringement Lawsuit regarding Drug Use Patent Pertaining to Oral Antipruritus Medication “REMITCH ® ” announced by Toray Industries, Inc. on May 27, 2025（PDF）	PU
14/05/25	Torii Pharmaceutical : Top-line Results of Bioequivalence Study between JTE-052 Lotion and Ointment, JAK Inhibitor, in Patients with Atopic Dermatitis in Japan（PDF）	PU
07/05/25	Torii Pharmaceutical : Announcement of Expression of Opinion in Support of the Tender Offer for Our Shares by Shionogi & Co., Ltd. and Recommendation to Tender Shares in the Tender Offer（PDF）	PU
07/05/25	Torii Pharmaceutical : Notice Regarding Revision of the Interim and Year-end Dividend Forecasts (Nil Dividend) for the Fiscal Year Ending December 2025（PDF）	PU
07/02/25	Torii Pharmaceutical : has announced Medium Term Management Plan 2025 2027（PDF）	PU
07/02/25	Torii Pharmaceutical : Announcement Regarding Changes of Representative Director and Officers（PDF）	PU
06/12/24	Torii Pharmaceutical : Files New Drug Application of TO-208 for the Treatment of Molluscum Contagiosum in Japan（PDF）	PU
27/09/24	Torii Pharmaceutical : Annual Report Document	PU
27/09/24	Torii Pharmaceutical : Annual Report Document	PU
27/09/24	Torii Pharmaceutical : Annual Report Document	PU
27/09/24	Torii Pharmaceutical : Annual Report Document	PU
27/09/24	Torii Pharmaceutical : Annual Report Document	PU
15/08/24	Torii Pharmaceutical : Listing on the Japanese National Health Insurance Drug Price List and Launch of VTAMA® Cream 1% in Japan（PDF）	PU
24/06/24	Torii Pharmaceutical : JT Receives Manufacturing and Marketing Approval of VTAMA® Cream 1% for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	PU
31/05/24	Torii Pharmaceutical : Positive Top line Results of Phase 3 Clinical Study (Comparative Study) of JTE 061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Pediatric Patients with Atopic Dermatitis in Japan	PU
18/12/23	Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	AQ
15/12/23	Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	PU
13/12/23	Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	PU
31/10/23	Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	PU
15/09/23	Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	PU
28/04/23	Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	PU
16/03/23	Torii Pharmaceutical : Views on Report from ISS, a Proxy Advisory Firm, On Proposals for ’s General Meeting of Shareholders	PU